A Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To estimate hematologic response rate of bexarotene monotherapy in subjects with relapsed/refractory AML or newly diagnosed AML who are unable to receive systemic chemotherapy.
Two months after 17th patient has started treatment with Bexarotene
Donald E. Tsai, MD, PhD
University of Pennsylvania
United States: Institutional Review Board
|Abramson Cancer Center Of University of Pennsylvania||Philadelphia, Pennsylvania 19104|